-transparent.png){kind=logo}
OBJECTIVE To evaluate the efficacy and tolerance of D0870 in the treatment of HIV-related fluconazole-resistant oro-oesophageal candidosis. METHODS Multicentre open study. METHODS HIV-seropositive patients with oro-oesophageal candidosis despite at least 7 days of treatment with fluconazole at doses of 100 mg per day or more. METHODS Patients received an initial dose of D0870 (150 mg), then 25 mg per day for 6 days. Symptoms and signs of candidosis were compared at entry and on days 3 and 7 of treatment. At each visit, samples were taken for safety monitoring and for in vitro susceptibility testing of Candida isolates. Limited pharmacokinetic samples were taken on days 1 and 7. RESULTS Of 26 evaluable patients, 16 showed partial improvement, nine showed no improvement, and only one had full clearance of thrush by day 7. In vitro testing of the cleared patient's isolate suggested that it was susceptible to fluconazole. Symptoms of dysphagia cleared in 14 and improved in five of the 22 patients with presumptive oesophageal involvement at entry. Pharmacokinetic measurement showed wide variability in maximum D0870 levels recorded on day 1 (range, 0.07-0.34 mg/l) and susceptibility testing of isolates also showed a range of minimal inhibitory concentration values to D0870 (range, < 0.06-8 mg/l; median, 0.25 mg/l). When these data were combined with clinical response there was a strong suggestion that lack of symptomatic improvement was related to low plasma D0870 levels or to the presence of less D0870-susceptible isolates. Six patients were noted to have a fall in haemoglobin, three of whom were receiving concomitant therapy known to suppress bone marrow. Three patients reported headaches as adverse events that were attributed to study medication, but D0870 was well tolerated overall. CONCLUSIONS D0870 shows promise in the treatment of fluconazole-resistant oro-oesophageal candidosis and was well tolerated, although efficacy in this difficult-to-treat patient group was probably limited due to the inadequate plasma levels achieved in this pilot study with the low doses of D0870 administered.
J D Cartledge, and
D W Denning, and
B Dupont, and
N Clumeck, and
S De Wit, and
J Midgley, and
D A Hawkins, and
B G Gazzard
July 1995,
AIDS (London, England),
J D Cartledge, and
D W Denning, and
B Dupont, and
N Clumeck, and
S De Wit, and
J Midgley, and
D A Hawkins, and
B G Gazzard
January 1999,
Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology,
J D Cartledge, and
D W Denning, and
B Dupont, and
N Clumeck, and
S De Wit, and
J Midgley, and
D A Hawkins, and
B G Gazzard
January 1989,
Scandinavian journal of infectious diseases,
J D Cartledge, and
D W Denning, and
B Dupont, and
N Clumeck, and
S De Wit, and
J Midgley, and
D A Hawkins, and
B G Gazzard
September 1990,
DICP : the annals of pharmacotherapy,
J D Cartledge, and
D W Denning, and
B Dupont, and
N Clumeck, and
S De Wit, and
J Midgley, and
D A Hawkins, and
B G Gazzard
August 1991,
The American journal of the medical sciences,
J D Cartledge, and
D W Denning, and
B Dupont, and
N Clumeck, and
S De Wit, and
J Midgley, and
D A Hawkins, and
B G Gazzard
June 1994,
AIDS (London, England),
J D Cartledge, and
D W Denning, and
B Dupont, and
N Clumeck, and
S De Wit, and
J Midgley, and
D A Hawkins, and
B G Gazzard
August 1989,
Wiener medizinische Wochenschrift (1946),
J D Cartledge, and
D W Denning, and
B Dupont, and
N Clumeck, and
S De Wit, and
J Midgley, and
D A Hawkins, and
B G Gazzard
January 1989,
Diagnostic microbiology and infectious disease,
J D Cartledge, and
D W Denning, and
B Dupont, and
N Clumeck, and
S De Wit, and
J Midgley, and
D A Hawkins, and
B G Gazzard
December 1998,
Mycoses,
J D Cartledge, and
D W Denning, and
B Dupont, and
N Clumeck, and
S De Wit, and
J Midgley, and
D A Hawkins, and
B G Gazzard
June 1997,
The Journal of antimicrobial chemotherapy,
